Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences accrued restructuring liability ($M) ($M)
Form 10-Q / 10-K Restructuring Note
Latest, FY2025
61
Period ended Dec 31, 2025
Change on a year earlier
-34.4%
93 in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Accrued restructuring liability ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 61 | -34.4% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 93 | – | Form 10-K (filed 2025-02-28) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Accrued restructuring liability ($M) ($M), annual FY2024–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/restruct_reserve
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.